ES2271013T3 - Ligando de proteina que se fija al calcio por induccion neuronal aguda de tipo 1. - Google Patents

Ligando de proteina que se fija al calcio por induccion neuronal aguda de tipo 1. Download PDF

Info

Publication number: ES2271013T3
Authority: ES; Spain
Prior art keywords: sequence; polypeptide; polynucleotide; seq; baselineskip
Prior art date: 2000-03-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES01936104T

Other languages

English (en)

Spanish (es)

Inventor

Izaak Den Daas

Klaus Ducker

Bjorn Hock

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Merck Patent GmbH

Original Assignee

Merck Patent GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-21

Filing date

2001-03-20

Publication date

2007-04-16

2001-03-20 Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH

2007-04-16 Application granted granted Critical

2007-04-16 Publication of ES2271013T3 publication Critical patent/ES2271013T3/es

2021-03-20 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

108090000623 proteins and genes Proteins 0.000 title claims abstract description 63
102000004169 proteins and genes Human genes 0.000 title claims abstract description 28
230000027455 binding Effects 0.000 title description 7
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title description 2
230000001154 acute effect Effects 0.000 title description 2
239000011575 calcium Substances 0.000 title description 2
229910052791 calcium Inorganic materials 0.000 title description 2
230000006698 induction Effects 0.000 title description 2
230000001537 neural effect Effects 0.000 title description 2
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 202
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 199
229920001184 polypeptide Polymers 0.000 claims abstract description 193
108091033319 polynucleotide Proteins 0.000 claims abstract description 117
102000040430 polynucleotide Human genes 0.000 claims abstract description 117
239000002157 polynucleotide Substances 0.000 claims abstract description 117
239000003446 ligand Substances 0.000 claims abstract description 42
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 25
108020001507 fusion proteins Proteins 0.000 claims abstract description 15
102000037865 fusion proteins Human genes 0.000 claims abstract description 15
230000014509 gene expression Effects 0.000 claims description 27
230000000295 complement effect Effects 0.000 claims description 7
239000012528 membrane Substances 0.000 claims description 3
239000013604 expression vector Substances 0.000 claims 2
238000000034 method Methods 0.000 description 70
210000004027 cell Anatomy 0.000 description 38
108020004414 DNA Proteins 0.000 description 36
108091032973 (ribonucleotides)n+m Proteins 0.000 description 28
239000002773 nucleotide Substances 0.000 description 26
125000003729 nucleotide group Chemical group 0.000 description 26
239000013615 primer Substances 0.000 description 25
235000018102 proteins Nutrition 0.000 description 25
201000010099 disease Diseases 0.000 description 19
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
235000001014 amino acid Nutrition 0.000 description 17
239000012634 fragment Substances 0.000 description 17
239000013598 vector Substances 0.000 description 17
150000001413 amino acids Chemical class 0.000 description 16
241001465754 Metazoa Species 0.000 description 15
150000001875 compounds Chemical class 0.000 description 15
241000282414 Homo sapiens Species 0.000 description 14
239000002299 complementary DNA Substances 0.000 description 14
239000000203 mixture Substances 0.000 description 13
238000004519 manufacturing process Methods 0.000 description 11
108020004999 messenger RNA Proteins 0.000 description 11
108091028043 Nucleic acid sequence Proteins 0.000 description 10
240000004808 Saccharomyces cerevisiae Species 0.000 description 10
230000000694 effects Effects 0.000 description 10
230000003993 interaction Effects 0.000 description 10
239000000556 agonist Substances 0.000 description 9
239000005557 antagonist Substances 0.000 description 9
238000005516 engineering process Methods 0.000 description 9
239000000047 product Substances 0.000 description 9
230000003321 amplification Effects 0.000 description 8
238000001514 detection method Methods 0.000 description 8
230000004048 modification Effects 0.000 description 8
238000012986 modification Methods 0.000 description 8
238000003199 nucleic acid amplification method Methods 0.000 description 8
102000039446 nucleic acids Human genes 0.000 description 8
108020004707 nucleic acids Proteins 0.000 description 8
150000007523 nucleic acids Chemical class 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
125000003275 alpha amino acid group Chemical group 0.000 description 7
210000000349 chromosome Anatomy 0.000 description 7
108020003175 receptors Proteins 0.000 description 7
102000005962 receptors Human genes 0.000 description 7
239000000523 sample Substances 0.000 description 7
230000009261 transgenic effect Effects 0.000 description 7
108700028369 Alleles Proteins 0.000 description 6
108020004635 Complementary DNA Proteins 0.000 description 6
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
241000700605 Viruses Species 0.000 description 6
238000009472 formulation Methods 0.000 description 6
230000002068 genetic effect Effects 0.000 description 6
238000009396 hybridization Methods 0.000 description 6
230000035772 mutation Effects 0.000 description 6
239000013612 plasmid Substances 0.000 description 6
229960005486 vaccine Drugs 0.000 description 6
238000004458 analytical method Methods 0.000 description 5
230000004071 biological effect Effects 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
238000003780 insertion Methods 0.000 description 5
230000037431 insertion Effects 0.000 description 5
230000008569 process Effects 0.000 description 5
238000000746 purification Methods 0.000 description 5
238000006467 substitution reaction Methods 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
230000004913 activation Effects 0.000 description 4
238000003556 assay Methods 0.000 description 4
230000008827 biological function Effects 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
238000010367 cloning Methods 0.000 description 4
210000001072 colon Anatomy 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
230000028993 immune response Effects 0.000 description 4
239000000463 material Substances 0.000 description 4
230000004481 post-translational protein modification Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
238000010396 two-hybrid screening Methods 0.000 description 4
102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
108091026890 Coding region Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
108060003951 Immunoglobulin Proteins 0.000 description 3
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
102000006382 Ribonucleases Human genes 0.000 description 3
108010083644 Ribonucleases Proteins 0.000 description 3
238000012300 Sequence Analysis Methods 0.000 description 3
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
238000007792 addition Methods 0.000 description 3
230000004075 alteration Effects 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
238000004132 cross linking Methods 0.000 description 3
125000004122 cyclic group Chemical group 0.000 description 3
238000005755 formation reaction Methods 0.000 description 3
230000006870 function Effects 0.000 description 3
230000004927 fusion Effects 0.000 description 3
210000004408 hybridoma Anatomy 0.000 description 3
102000018358 immunoglobulin Human genes 0.000 description 3
238000002955 isolation Methods 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
230000011987 methylation Effects 0.000 description 3
238000007069 methylation reaction Methods 0.000 description 3
230000026731 phosphorylation Effects 0.000 description 3
238000006366 phosphorylation reaction Methods 0.000 description 3
230000005855 radiation Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
238000012216 screening Methods 0.000 description 3
230000028327 secretion Effects 0.000 description 3
241000894007 species Species 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000000758 substrate Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
-1 that is Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000001890 transfection Methods 0.000 description 3
229940035893 uracil Drugs 0.000 description 3
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
241000699800 Cricetinae Species 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
239000003155 DNA primer Substances 0.000 description 2
238000001712 DNA sequencing Methods 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
108010001515 Galectin 4 Proteins 0.000 description 2
102100039556 Galectin-4 Human genes 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
102000005936 beta-Galactosidase Human genes 0.000 description 2
108010005774 beta-Galactosidase Proteins 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000002759 chromosomal effect Effects 0.000 description 2
238000012912 drug discovery process Methods 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
238000000605 extraction Methods 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
238000013537 high throughput screening Methods 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
210000003917 human chromosome Anatomy 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000013507 mapping Methods 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
238000000520 microinjection Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
210000002741 palatine tonsil Anatomy 0.000 description 2
210000000496 pancreas Anatomy 0.000 description 2
230000000849 parathyroid Effects 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
210000002826 placenta Anatomy 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
239000002987 primer (paints) Substances 0.000 description 2
230000009145 protein modification Effects 0.000 description 2
238000003757 reverse transcription PCR Methods 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000014616 translation Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
238000010798 ubiquitination Methods 0.000 description 2
230000034512 ubiquitination Effects 0.000 description 2
241001515965 unidentified phage Species 0.000 description 2
210000004291 uterus Anatomy 0.000 description 2
KUWPCJHYPSUOFW-YBXAARCKSA-N 2-nitrophenyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-YBXAARCKSA-N 0.000 description 1
ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
102400000069 Activation peptide Human genes 0.000 description 1
101800001401 Activation peptide Proteins 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
241000228212 Aspergillus Species 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
241000271566 Aves Species 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
241000345998 Calamus manan Species 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
238000009007 Diagnostic Kit Methods 0.000 description 1
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
101100184531 Drosophila melanogaster Mo25 gene Proteins 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
108010093488 His-His-His-His-His-His Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000685982 Homo sapiens NAD(+) hydrolase SARM1 Proteins 0.000 description 1
101000604540 Homo sapiens PRKCA-binding protein Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
101100494453 Mus musculus Cab39 gene Proteins 0.000 description 1
101000805948 Mus musculus Harmonin Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
102100023356 NAD(+) hydrolase SARM1 Human genes 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102100038730 PRKCA-binding protein Human genes 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
108700008625 Reporter Genes Proteins 0.000 description 1
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
241000256248 Spodoptera Species 0.000 description 1
241000295644 Staphylococcaceae Species 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
241000700647 Variola virus Species 0.000 description 1
241000219995 Wisteria Species 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
230000032683 aging Effects 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000010516 arginylation Effects 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000006287 biotinylation Effects 0.000 description 1
238000007413 biotinylation Methods 0.000 description 1
210000002459 blastocyst Anatomy 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
239000000872 buffer Substances 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
238000005277 cation exchange chromatography Methods 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000017858 demethylation Effects 0.000 description 1
238000010520 demethylation reaction Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
210000002472 endoplasmic reticulum Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000001400 expression cloning Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
230000022244 formylation Effects 0.000 description 1
238000006170 formylation reaction Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
230000006251 gamma-carboxylation Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
238000012188 high-throughput screening assay Methods 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
238000012872 hydroxylapatite chromatography Methods 0.000 description 1
230000033444 hydroxylation Effects 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000026045 iodination Effects 0.000 description 1
238000006192 iodination reaction Methods 0.000 description 1
238000005304 joining Methods 0.000 description 1
239000002523 lectin Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
238000011068 loading method Methods 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
238000002493 microarray Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
210000000287 oocyte Anatomy 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
210000001322 periplasm Anatomy 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229940080469 phosphocellulose Drugs 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000001902 propagating effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
208000009305 pseudorabies Diseases 0.000 description 1
229940043131 pyroglutamate Drugs 0.000 description 1
230000006340 racemization Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
235000012950 rattan cane Nutrition 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
235000004400 serine Nutrition 0.000 description 1
125000003607 serino group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
235000013599 spices Nutrition 0.000 description 1
208000020431 spinal cord injury Diseases 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
230000019635 sulfation Effects 0.000 description 1
238000005670 sulfation reaction Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
235000008521 threonine Nutrition 0.000 description 1
125000000341 threoninyl group Chemical class [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
230000009452 underexpressoin Effects 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Zoology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Immunology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Investigating Or Analysing Biological Materials (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Seasonings (AREA)

ES01936104T 2000-03-21 2001-03-20 Ligando de proteina que se fija al calcio por induccion neuronal aguda de tipo 1. Expired - Lifetime ES2271013T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00106110		2000-03-21
EP00106110		2000-03-21

Publications (1)

Publication Number	Publication Date
ES2271013T3 true ES2271013T3 (es)	2007-04-16

Family

ID=8168173

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES01936104T Expired - Lifetime ES2271013T3 (es)	2000-03-21	2001-03-20	Ligando de proteina que se fija al calcio por induccion neuronal aguda de tipo 1.

Country Status (10)

Country	Link
US (1)	US20030148446A1 (de)
EP (1)	EP1266008B1 (de)
JP (1)	JP2003527848A (de)
AT (1)	ATE338123T1 (de)
CA (1)	CA2403436A1 (de)
DE (1)	DE60122684T2 (de)
DK (1)	DK1266008T3 (de)
ES (1)	ES2271013T3 (de)
PT (1)	PT1266008E (de)
WO (1)	WO2001070771A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007096854A1 (en) *	2006-02-21	2007-08-30	The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin	Compositions and methods for modulating an immune response

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL364763A1 (en) *	1999-06-22	2004-12-13	Merck Patent Gmbh	Head trauma induced cytoplasmatic calcium binding protein

2001
- 2001-03-20 WO PCT/EP2001/003149 patent/WO2001070771A2/en not_active Ceased
- 2001-03-20 JP JP2001568972A patent/JP2003527848A/ja active Pending
- 2001-03-20 DK DK01936104T patent/DK1266008T3/da active
- 2001-03-20 PT PT01936104T patent/PT1266008E/pt unknown
- 2001-03-20 CA CA002403436A patent/CA2403436A1/en not_active Abandoned
- 2001-03-20 DE DE60122684T patent/DE60122684T2/de not_active Expired - Fee Related
- 2001-03-20 EP EP01936104A patent/EP1266008B1/de not_active Expired - Lifetime
- 2001-03-20 US US10/239,079 patent/US20030148446A1/en not_active Abandoned
- 2001-03-20 AT AT01936104T patent/ATE338123T1/de not_active IP Right Cessation
- 2001-03-20 ES ES01936104T patent/ES2271013T3/es not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US20030148446A1 (en)	2003-08-07
DE60122684T2 (de)	2007-08-23
PT1266008E (pt)	2007-01-31
DE60122684D1 (de)	2006-10-12
CA2403436A1 (en)	2001-09-27
WO2001070771A2 (en)	2001-09-27
EP1266008A2 (de)	2002-12-18
JP2003527848A (ja)	2003-09-24
EP1266008B1 (de)	2006-08-30
WO2001070771A3 (en)	2002-05-02
ATE338123T1 (de)	2006-09-15
DK1266008T3 (da)	2006-11-27

Publication	Publication Date	Title
PT1098972E (pt)	2010-12-14	Proteína semelhante a proteína especificamente neuroendócrina e adnc codificante
ES2231537T3 (es)	2005-05-16	Un nuevo miembro de la familia de receptores epha.
ES2258090T3 (es)	2006-08-16	Gen humano de tipo wingless.
ES2271013T3 (es)	2007-04-16	Ligando de proteina que se fija al calcio por induccion neuronal aguda de tipo 1.
US6183990B1 (en)	2001-02-06	Compounds
US7166701B2 (en)	2007-01-23	Human survivin interacting protein 1 (SIP-1)
ES2272458T3 (es)	2007-05-01	Nuevo factor de transcripcion carp-2.
US20030096313A1 (en)	2003-05-22	Novel serine-threonine kinase-4
US6274380B1 (en)	2001-08-14	Cacnglike3 polynucleotides and expression systems
WO2001014423A1 (en)	2001-03-01	Identification of three putative calcium channel vanilrep peptides
ES2351685T3 (es)	2011-02-09	Proteína similar a la proteína específica neuroendocrina y adnc codificante.
US20020001823A1 (en)	2002-01-03	Novel compounds
CA2409686A1 (en)	2001-11-08	Serine-threonine kinase
EP1278847A1 (de)	2003-01-29	Neue gtpase-aktivierende protein 1
US20050058647A1 (en)	2005-03-17	Phosphodiesterase type 7b
US20040086973A1 (en)	2004-05-06	Identification of a novel cam-kinase II inhibitor
US7432348B2 (en)	2008-10-07	180 kD protein that interacts with protein histidine phosphatase 1
EP1170365A1 (de)	2002-01-09	Ein Mitglied der Ionenkanal Polypeptide Familie; Vanilrep4
US20020004223A1 (en)	2002-01-10	FHAR1, a new ring finger protein
US20070292921A1 (en)	2007-12-20	tRNA synthetases, metRS
US20050074839A1 (en)	2005-04-07	Novel survivin interacting protein tpr1
US20060205641A1 (en)	2006-09-14	VANILREP4 polypeptides and VANILREP4 polynucleotides
US20040039166A1 (en)	2004-02-26	Iapl-3 a novel protein inhibitor of apoptosis protein
US20050070002A1 (en)	2005-03-31	Histidine phosphatase interacting protein with 120kd
US20030207293A1 (en)	2003-11-06	Cryptic-like secreted protein